Levothyroxin bei euthyreoter Autoimmunthyreoiditis und Typ 1 Diabetes mellitus: eine randomisierte, kontrollierte Studie

Abstract

Our objective was to determine wheter levothyroxine (L-T4) treatment prevents the clinical manifestation of AIT in euthyroid subjects with T1D. We conducted a prospective, randomized, open, controlled trial. L-T4 was given for 24 months in the treatment group, followerd by an additional observation period of 6 months in both groups. Mean thyroid volume decreased in the treatment group after 24 months (-0,6 SD score) and increased in the observation group (+1,11 SD score; p = 0,0218). Conclusions: In this study in euthyroid patients with AIT and T1D, L-T4 treatment reduced thyroid volume but had no effect on thyroid function and serum autoantibody levels.